The Structural Maturity Era in Valvular Heart Disease

Executive summary

Between January 2025 and March 2026, valvular heart disease crossed a strategic threshold.

For two decades, the central question in structural heart disease was “Can we intervene?” That question has been answered. The question that now governs every MDT discussion, every imaging report, and every consent conversation is different: “When do we intervene, how early, and what does this first decision commit the patient to for the next twenty years?”

This transformation is not theoretical. The 2025 ESC/EACTS Guidelines for the management of valvular heart disease, published at ESC Congress in Madrid, August 2025, codify it. The PARTNER 3 seven-year data, the EARLY TAVR trial, the TRILUMINATE two-year outcomes, and the emergence of dedicated transcatheter aortic regurgitation platforms have collectively moved the field from device enthusiasm to strategic architecture.

This article provides a structured, consultant-level breakdown of every major valve domain. Each section follows the same clinical logic: guideline change, pivotal evidence, imaging upgrade, clinical impact, practical algorithm, and consultant pearls. It is designed to be read once and referenced repeatedly, the kind of resource that sits on your desktop, not in your recycling bin.

The Guideline Shift That Changes Everything

The single most system-altering recommendation in the 2025 ESC/EACTS guidelines is the reduction of the TAVI age threshold from ≥75 years to ≥70 years for patients with tricuspid aortic valve morphology and suitable anatomy. This is not merely an administrative change. It fundamentally reconfigures referral pathways, MDT case-mix, and, critically, demands that every Heart Valve Centre develops a coherent lifetime management strategy before the first intervention.

The guidelines simultaneously strengthen the emphasis on Heart Valve Centre governance, CT integration in discordant severity assessment, and, for the first time in such explicit terms, lifetime procedural planning as a Class I principle. The era of evaluating TAVI and SAVR as standalone procedures is over. Every index intervention is now the first move in a multi-decade chess game.

The Evidence That Built This Recommendation

Individual endpoints at seven years were similarly concordant. All-cause mortality was 19.5% after TAVI and 16.8% after SAVR (HR 1.17; p=0.31). Stroke rates were essentially identical (8.5% vs 8.1%). Bioprosthetic valve failure, assessed by VARC-3 criteria, was low and comparable in both groups (6.9% vs 7.3%). Valve haemodynamics remained stable and virtually equivalent, with mean aortic valve gradients of 13.1 mmHg after TAVI versus 12.1 mmHg after SAVR.

The number needed to treat was just six at two years. Perhaps more revealing: within the surveillance arm, 47% of patients required aortic valve replacement within twelve months, and 87% ultimately crossed over to intervention. Approximately 40% of those who converted did so with advanced symptoms, NYHA III-IV heart failure, pulmonary oedema, or syncope. The so-called “safe window” of watchful waiting was, in reality, a period of unpredictable and often precipitous clinical deterioration.

Imaging Upgrades: CT Is No Longer Optional

The 2025 guidelines elevate CT calcium scoring from a useful adjunct to an essential diagnostic tool in discordant aortic stenosis. CT calcium scoring now serves as both the adjudicator in low-flow low-gradient AS with preserved ejection fraction and the confirmation tool in cases where echocardiographic severity indices conflict. The sex-specific thresholds (Agatston ≥2000 in men, ≥1200 in women for very likely severe AS) remain the reference standard.

The integration of CT into the diagnostic algorithm is not about replacing echocardiography, it is about acknowledging that CT calcium scoring has moved from supportive to decisive.

Clinical Impact: The Conversation Has Changed

The MDT conversation has evolved from “TAVI versus SAVR?” to “What is the lifetime valve strategy?” Every first intervention must now be evaluated through the lens of: coronary re-access planning, valve-in-valve feasibility, small annulus foresight, and redo pathway mapping. The 2025 guidelines explicitly require that Heart Valve Centres document lifetime management planning.

Why AR Matters Now

For decades, pure native aortic regurgitation in high-surgical-risk patients represented a therapeutic dead end. Unlike aortic stenosis, where calcification provides a scaffold for transcatheter valve anchoring, the non-calcified, compliant annulus of AR patients offered no reliable fixation. That era is ending.

The technical nuances are critical. AR TAVI is not AS TAVI. The absence of annular calcification fundamentally changes anchoring mechanics. Root geometry variability demands meticulous CT assessment. Oversizing carries catastrophic consequences. Device-specific experience and dedicated centre expertise will determine outcomes in this space.

The Phenotype Revolution

The 2025 ESC/EACTS guidelines formalise what experienced valve operators have known for years: treating “mitral regurgitation” as a single disease is a path to suboptimal outcomes. The guidelines now mandate explicit phenotype classification into three mechanistically distinct entities: primary (degenerative) MR, ventricular secondary MR, and, for the first time in a major guideline, atrial secondary MR as a formally recognised phenotype.

This is not a semantic distinction. Each phenotype has a different natural history, a different imaging signature, a different response to intervention, and a different set of failure modes. Treating atrial SMR like ventricular SMR, or managing primary MR without assessing repairability, is no longer defensible.

Key Evidence: What Changed in 2025

The Evidence Base Has Arrived

For decades, tricuspid regurgitation was the “forgotten valve”, acknowledged as prognostically important, but rarely intervened upon. That era is over. TR now receives unprecedented attention in the 2025 ESC/EACTS guidelines, with new recommendations for both surgical and transcatheter intervention, and a mandatory comprehensive Heart Team evaluation before any therapeutic decision.

At two years, 84% of TEER-treated patients maintained TR severity of moderate or less. Heart failure hospitalisation rates were significantly reduced: 0.19 versus 0.26 events per patient-year (HR 0.72; p=0.02), representing a 28% relative risk reduction. KCCQ improvements exceeded 15 points and were sustained. The safety profile remained excellent, no device embolisation, no thrombosis, no pacemaker-requiring conduction disturbance.

Crucially, after year one, more than half of eligible control patients crossed over to TEER, a finding that, while complicating intention-to-treat analysis, powerfully validates the clinical demand for this therapy.

The 2025 guidelines reframe prosthetic valve management from episodic surveillance to longitudinal architectural planning. Three developments drive this shift.

First, CT is now increasingly essential in suspected leaflet thrombosis, subclinical and clinical. Hypo-attenuated leaflet thickening (HALT), once an incidental CT finding, is now formally recognised, though its clinical significance remains contextual. The guidelines recommend CT when clinical suspicion exists but do not mandate routine CT surveillance in asymptomatic patients.

Second, redo-TAVI and valve-in-valve (ViV) planning is becoming routine. As the population of patients living with transcatheter bioprostheses grows, the need for systematic redo pathway planning has become operationally urgent. Coronary access after ViV, commissural alignment, neo-LVOT obstruction risk, and small-annulus considerations must all be anticipated at the index procedure.

Third, the antithrombotic recommendations have been refined. Routine DAPT after valve procedures is discouraged. Mechanical valves require lifelong VKA; DOACs remain contraindicated. Post-TAVI, low-dose aspirin alone is preferred unless an independent OAC indication exists.

Infective endocarditis is increasingly a disease of the structural heart era. TAVI-associated IE has been recognised as a high-mortality subgroup with distinct diagnostic and therapeutic challenges. The 2025 guidelines formalise the Endocarditis Team as a mandatory governance structure and integrate PET-CT into the diagnostic algorithm for prosthetic and device-related IE.

Imaging Algorithm: Stepwise Escalation

The diagnostic pathway follows a clear escalation: TTE as the first-line screening tool; TOE when TTE is non-diagnostic or when prosthetic valve, device, or perivalvular complications are suspected; and PET-CT plus cardiac CT in prosthetic or equivocal cases.

The Duke criteria, while still relevant, are acknowledged as insufficient in isolation, particularly for prosthetic valve and device-related IE, where sensitivity is limited.

Clinical Impact

IE management in 2026 requires multidisciplinary coordination from the point of clinical suspicion. The Endocarditis Team, cardiologist, cardiac surgeon, infectious disease specialist, microbiologist, and imaging specialist at minimum, must be involved in all cases of confirmed or suspected IE. Early surgical consideration, imaging escalation, and structured source-control thinking are the pillars of modern IE management.

NICE Guidance: Scope and intended use

NICE publishes both (a) procedure-focused guidance (Interventional Procedures/HealthTech guidance) and (b) an overarching clinical guideline, NG208 (2021): Heart valve disease presenting in adults: investigation and management. Procedure guidance (e.g., TAVI and percutaneous mitral leaflet repair) primarily addresses whether a procedure is acceptable in terms of safety and efficacy in defined contexts; it does not function as a comprehensive, end-to-end structural valve management framework.

NICE does address transcatheter tricuspid leaflet repair for TR (HTG632, formerly IPG731), but NICE guidance (including NG208 and current procedure guidance) does not currently operationalise many contemporary structural-era concepts emphasised in ESC/EACTS frameworks, such as explicit lifetime valve strategy documentation, ESC age-threshold framing (e.g., ≥70 TAVI preference in suitable tricuspid AS anatomy), and formal guideline-level handling of newer phenotype constructs (e.g., atrial secondary MR) as a distinct decision pathway. ^[20]

For specialist decision-making in UK Heart Valve Centres, clinical governance is therefore typically anchored in ESC/EACTS guideline recommendations, supported by BSE/EACVI imaging standards, relevant UK professional society guidance, and NHS England service specifications/commissioning positions where applicable.

What Drives Clinical Decisions vs Service Delivery

In UK practice, NICE guidance (including NG208 and procedure-specific recommendations) and NHS England commissioning frameworks shape adoption, commissioning and service delivery within the NHS. ESC/EACTS guidelines provide additional contemporary clinical decision frameworks widely used within specialist Heart Valve Centres. High-quality valve care requires alignment between international evidence-based guidance and local governance structures.

BSE / EACVI Imaging Standards

All echocardiographic assessments referenced in this document should conform to BSE minimum dataset requirements and EACVI quantification standards. Particular attention should be paid to: 3D quantification of MR (mandatory for TEER assessment); CT calcium scoring methodology for discordant AS; and standardised reporting templates that capture phenotype, mechanism, severity, and MDT-relevant decision data.

The following templates provide MDT-friendly reporting language for common clinical scenarios.

Adapt to local protocols.

Template 1: Severe AS , Pre-Intervention Assessment

Echocardiographic assessment confirms severe aortic stenosis: peak velocity [X] m/s, mean gradient [X] mmHg, AVA [X] cm². LV function preserved/impaired (EF [X]%). No significant concomitant valvular disease / [describe if present]. CT calcium scoring: [X] Agatston units (threshold for sex-specific severe AS: ≥2000 men, ≥1200 women). Anatomy: tricuspid/bicuspid aortic valve. Clinical status/Frailty score; [X, Description].

Recommended for Heart Valve Centre MDT discussion re: intervention strategy and lifetime management planning per 2025 ESC/EACTS guidelines.

Template 2: Mitral Regurgitation , Phenotype & Severity

Severe mitral regurgitation confirmed. Phenotype: [primary (degenerative) / ventricular secondary / atrial secondary]. Mechanism: [P2 prolapse with flail / annular dilatation with AF / posterior leaflet tethering with LV remodelling]. Quantification: EROA [X] cm², regurgitant volume [X] ml (3D-derived). LV function: EF [X]%, LVESD [X] mm. LA volume index [X] ml/m². SPAP [X] mmHg. Suitability for TEER: [favourable / unfavourable , specify limiting anatomy]. Clinical status/Frailty score; [X, Description].

Recommended for MDT discussion re: intervention timing and modality.

Template 3: Tricuspid Regurgitation , Severity & RV Assessment

Severe/torrential tricuspid regurgitation confirmed. Phenotype: [AF-driven / RV-driven / primary]. Coaptation gap: [X] mm. Tethering height: [X] mm. RV function: TAPSE [X] mm, RV S’ [X] cm/s, RV FAC [X]%, RV free wall strain [X]%. RA volume [X] ml. SPAP [X] mmHg. Evidence of RV-PA uncoupling: [yes/no]. Hepatic vein flow reversal: [present/absent]. Clinical status/Frailty score; [X, Description].

Recommended for Heart Valve Centre MDT discussion re: transcatheter vs surgical intervention and timing assessment.

The real transformation of 2025-2026 is conceptual, not technological.

We have moved from asking whether a device works to asking how a single decision shapes the next two decades of a patient’s cardiovascular life. Valvular heart disease is no longer about intervention alone. It is about phenotype precision, imaging authority, timing optimisation, lifetime strategy, and multidisciplinary governance.

The 2025 ESC/EACTS guidelines codify this shift. The evidence provides the data to support it. The challenge now is implementation: building Heart Valve Networks that function in practice, not just on paper; training MDTs to think in decades rather than discharge summaries; and holding ourselves accountable to the standard these guidelines demand.

Structural heart disease has matured. The question is whether our programmes have.

References

1. Praz F, Borger MA, Lanz J, Marin-Cuartas M, Abreu A, Adamo M, et al. 2025 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2025;46(44):4635-4736. doi:10.1093/eurheartj/ehaf194
2. Leon MB, Mack MJ, Pibarot P, Hahn RT, Thourani VH, Kodali SH, et al. Transcatheter or surgical aortic-valve replacement in low-risk patients at 7 years. N Engl J Med. 2025 Oct 27. doi:10.1056/NEJMoa2509766
3. Généreux P, Schwartz A, Oldemeyer JB, Pibarot P, Cohen DJ, Blanke P, et al. Transcatheter aortic-valve replacement for asymptomatic severe aortic stenosis. N Engl J Med. 2025;392:217-227. doi:10.1056/NEJMoa2405880
4. Kar S, Makkar RR, Whisenant BK, et al. Two-year outcomes of transcatheter edge-to-edge repair for severe tricuspid regurgitation: the TRILUMINATE pivotal randomized controlled trial. Circulation. 2025;Epub ahead of print. doi:10.1161/CIRCULATIONAHA.125.074536
5. Tang GHL, Hahn RT, Whisenant BK, et al. Tricuspid transcatheter edge-to-edge repair for severe tricuspid regurgitation: 1-year outcomes from the TRILUMINATE randomized cohort. J Am Coll Cardiol. 2025;85(3):235-246. doi:10.1016/j.jacc.2024.10.086
6. Hahn RT, Makkar R, Thourani VH, et al. Transcatheter valve replacement in severe tricuspid regurgitation (TRISCEND II). N Engl J Med. 2025;392:115-126. doi:10.1056/NEJMoa2401918
7. Arnold SV, Goates S, Sorajja P, Adams DH, von Bardeleben RS, Kapadia SR, et al. Health status after transcatheter tricuspid-valve repair in patients with severe tricuspid regurgitation. J Am Coll Cardiol. 2024;83(1):1-13. doi:10.1016/j.jacc.2023.10.008
8. Sorajja P, Whisenant B, Hamid N, et al. Transcatheter repair for patients with tricuspid regurgitation (TRILUMINATE Pivotal). N Engl J Med. 2023;388:1833-1842. doi:10.1056/NEJMoa2300525
9. Loganath K, Craig NJ, Everett RJ, et al. Early intervention in patients with asymptomatic severe aortic stenosis and myocardial fibrosis: the EVOLVED randomized clinical trial. JAMA. 2025;333:213-221. doi:10.1001/jama.2024.22730
10. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43(7):561-632. doi:10.1093/eurheartj/ehab395
11. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients (PARTNER 3). N Engl J Med. 2019;380:1695-1705. doi:10.1056/NEJMoa1814052
12. Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure (COAPT). N Engl J Med. 2018;379:2307-2318. doi:10.1056/NEJMoa1806640
13. NICE Interventional Procedures Guidance [IPG586]. Transcatheter aortic valve implantation for aortic stenosis. NICE; 2017.
14. NICE Interventional Procedures Guidance [IPG649]. Transcatheter mitral valve leaflet repair for mitral regurgitation. NICE; 2019.
15. Banovic M, Putnik S, Penicka M, et al. Aortic valve replacement versus conservative treatment in asymptomatic severe aortic stenosis: the AVATAR trial. Circulation. 2022;145(9):648-658. doi:10.1161/CIRCULATIONAHA.121.057639
16. Kang DH, Park SJ, Lee SA, et al. Early surgery or conservative care for asymptomatic aortic stenosis (RECOVERY). N Engl J Med. 2020;382:111-119. doi:10.1056/NEJMoa1912846
17. Makkar RR, Thourani VH, Vahl TP, et al. Transcatheter aortic valve implantation with the Trilogy valve for symptomatic native aortic regurgitation (ALIGN-AR): a pivotal, multicentre, single-arm, investigational device exemption study. Lancet. 2025;406(10521):2757-2771. doi:10.1016/S0140-6736(25)02215-9
18. Tsunamoto H, Yamamoto M, Kagase A, et al. Using transmitral pressure gradients and residual mitral regurgitation to optimize outcome after transcatheter edge-to-edge repair. J Am Coll Cardiol. 2025;86(19):1684-1700. doi:10.1016/j.jacc.2025.07.041
19. Guerrero ME, Daniels DV, Makkar RR, et al. Percutaneous transcatheter valve replacement in individuals with mitral regurgitation unsuitable for surgery or transcatheter edge-to-edge repair: a prospective, multicountry, single-arm trial. Lancet. 2025;406(10519):2541-2550. doi:10.1016/S0140-6736(25)02073-2
20. National Institute for Health and Care Excellence. Transcatheter tricuspid valve leaflet repair for tricuspid regurgitation. HealthTech guidance 632 (formerly IPG731). Published 27 July 2022; migrated January 2026. URL: https://www.nice.org.uk/guidance/htg632